You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

249 Results
Regimen
Cancer Type:
Lung, 
Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
durvalumab (Compassionate)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dostarlimab,
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Drug
Other Name(s): Imfinzi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dexamethasone,
pomalidomide (Unfunded),
selinexor (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
DOXOrubicin,
trabectedin (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
En octobre 2024, le Programme ontarien de dépistage du cancer du sein a abaissé l’âge de début du dépistage de 50 à 40 ans. Cette page fournit de l’...
Drug
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Drug
Other Name(s): Tafinlar®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue, 
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
dacarbazine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - As monotherapy for the treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, based on criteria
Exceptional Access Program
    trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib,
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph

Pages